{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:01Z","timestamp":1793316241309,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1CA137443"],"award-info":[{"award-number":["UM1CA137443"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11060-023-04456-7","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T13:01:46Z","timestamp":1697893306000},"page":"101-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma"],"prefix":"10.1007","volume":"165","clinical-trial-number":[{"clinical-trial-number":"nct03216499","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Roy","family":"Strowd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ellingson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Burt","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"issue":"23","key":"4456_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA 318(23):2306. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"4456_CR2","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 314:2535. https:\/\/doi.org\/10.1001\/jama.2015.16669","journal-title":"JAMA"},{"issue":"10","key":"4456_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason W, van den Bent M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352(10):987\u2013996","journal-title":"NEJM"},{"issue":"9","key":"4456_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma\u202f: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916\u2013926. https:\/\/doi.org\/10.1016\/S1470-2045(12)70265-6","journal-title":"Lancet Oncol"},{"issue":"8","key":"4456_CR5","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/NEUONC\/NOAA106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-oncology 22(8):1073\u20131113. https:\/\/doi.org\/10.1093\/NEUONC\/NOAA106","journal-title":"Neuro-oncology"},{"issue":"20","key":"4456_CR6","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMOA1707358\/SUPPL_FILE\/NEJMOA1707358_DISCLOSURES.PDF","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMOA1707358\/SUPPL_FILE\/NEJMOA1707358_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"10","key":"4456_CR7","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373\u20131385. https:\/\/doi.org\/10.1016\/S1470-2045(17)30517-X","journal-title":"Lancet Oncol"},{"issue":"10","key":"4456_CR8","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/CNCR.33378","volume":"127","author":"DA Reardon","year":"2021","unstructured":"Reardon DA, Kim TM, Frenel JS et al (2021) Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127(10):1620\u20131629. https:\/\/doi.org\/10.1002\/CNCR.33378","journal-title":"Cancer"},{"issue":"7","key":"4456_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/JAMAONCOL.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003\u20131010. https:\/\/doi.org\/10.1001\/JAMAONCOL.2020.1024","journal-title":"JAMA Oncol"},{"key":"4456_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.semcdb.2005.03.007","volume":"16","author":"H Axelson","year":"2005","unstructured":"Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S (2005) Hypoxia-induced dedifferentiation of tumor cells\u2014a mechanism behind heterogeneity and aggressiveness of solid tumors. Semi Cell Dev Biol 16:554\u2013563","journal-title":"Semi Cell Dev Biol"},{"issue":"1","key":"4456_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL (2002) Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38\u201347. https:\/\/doi.org\/10.1038\/nrc704","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"4456_CR12","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.4161\/cc.8.20.9701","volume":"8","author":"JM Heddleston","year":"2009","unstructured":"Heddleston JM, Li Z, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20):3274\u20133284","journal-title":"Cell Cycle"},{"issue":"1","key":"4456_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2012","unstructured":"Keith B, Johnson RS, Simon MC (2012) HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12(1):9\u201322. https:\/\/doi.org\/10.1038\/nrc3183","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4456_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3349\/ymj.2017.58.3.489","volume":"58","author":"T Yu","year":"2017","unstructured":"Yu T, Tang B, Sun X (2017) Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J 58(3):489. https:\/\/doi.org\/10.3349\/ymj.2017.58.3.489","journal-title":"Yonsei Med J"},{"issue":"2","key":"4456_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ki.1997.77","volume":"51","author":"GL Semenza","year":"1997","unstructured":"Semenza GL, Agani F, Booth G et al (1997) Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 51(2):553\u2013555","journal-title":"Kidney Int"},{"issue":"5","key":"4456_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gad.1881410","volume":"24","author":"N Takeda","year":"2010","unstructured":"Takeda N, O\u2019Dea EL, Doedens A et al (2010) Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev 24(5):491\u2013501. https:\/\/doi.org\/10.1101\/gad.1881410","journal-title":"Genes Dev"},{"issue":"3","key":"4456_CR17","first-page":"205","volume":"7","author":"YZ Gu","year":"1998","unstructured":"Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7(3):205\u2013213","journal-title":"Gene Expr"},{"issue":"1","key":"4456_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409238.2013.838205","volume":"49","author":"VL Dengler","year":"2014","unstructured":"Dengler VL, Galbraith MD, Espinosa JM (2014) Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 49(1):1\u201315. https:\/\/doi.org\/10.3109\/10409238.2013.838205","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"7","key":"4456_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.trecan.2017.05.002","volume":"3","author":"S Rey","year":"2017","unstructured":"Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS (2017) Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer 3(7):529\u2013541. https:\/\/doi.org\/10.1016\/j.trecan.2017.05.002","journal-title":"Trends Cancer"},{"issue":"5","key":"4456_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/J.APSB.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W (2015) HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 5(5):378\u2013389. https:\/\/doi.org\/10.1016\/J.APSB.2015.05.007","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"4456_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/NRC1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891\u2013899. https:\/\/doi.org\/10.1038\/NRC1478","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4456_CR22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/NRN2175","volume":"8","author":"RK Jain","year":"2007","unstructured":"Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610\u2013622. https:\/\/doi.org\/10.1038\/NRN2175","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"4456_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.mrfmmm.2004.04.018","volume":"568","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Frieden BR (2004) Information dynamics in carcinogenesis and tumor growth. Mutat Res-Fundam Mol Mech Mutagen 568(2):259\u2013273. https:\/\/doi.org\/10.1016\/j.mrfmmm.2004.04.018","journal-title":"Mutat Res-Fundam Mol Mech Mutagen"},{"issue":"10","key":"4456_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/NRC.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O (2017) Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer 17(10):577\u2013593. https:\/\/doi.org\/10.1038\/NRC.2017.77","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4456_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S0360-3016(98)00360-5","volume":"42","author":"L Griffiths","year":"1998","unstructured":"Griffiths L, Stratford IJ (1998) The influence of elevated levels of platelet-derived endothelial cell growth factor\/thymidine phosphorylase on tumourigenicity, tumour growth, and oxygenation. Int J Radiat Oncol Biol Phys 42(4):877\u2013883. https:\/\/doi.org\/10.1016\/S0360-3016(98)00360-5","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"28","key":"4456_CR26","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1038\/SJ.ONC.1204500","volume":"20","author":"Q Shi","year":"2001","unstructured":"Shi Q, Le X, Wang B et al (2001) Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20(28):3751\u20133756. https:\/\/doi.org\/10.1038\/SJ.ONC.1204500","journal-title":"Oncogene"},{"issue":"5","key":"4456_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/CDD.2010.150","volume":"18","author":"AB Hjelmeland","year":"2011","unstructured":"Hjelmeland AB, Wu Q, Heddleston JM et al (2011) Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 18(5):829\u2013840. https:\/\/doi.org\/10.1038\/CDD.2010.150","journal-title":"Cell Death Differ"},{"issue":"6","key":"4456_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3174\/AJNR.A6063","volume":"40","author":"YL Wang","year":"2019","unstructured":"Wang YL, Yao J, Chakhoyan A et al (2019) Association between tumor acidity and hypervascularity in human gliomas using pH-weighted amine chemical exchange saturation transfer echo-planar imaging and dynamic susceptibility contrast perfusion MRI at 3T. AJNR Am J Neuroradiol 40(6):979\u2013986. https:\/\/doi.org\/10.3174\/AJNR.A6063","journal-title":"AJNR Am J Neuroradiol"},{"issue":"9","key":"4456_CR29","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/NEUONC\/NOZ078","volume":"21","author":"J Yao","year":"2019","unstructured":"Yao J, Chakhoyan A, Nathanson DA et al (2019) Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-oncology 21(9):1184\u20131196. https:\/\/doi.org\/10.1093\/NEUONC\/NOZ078","journal-title":"Neuro-oncology"},{"issue":"22","key":"4456_CR30","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMOA2103425\/SUPPL_FILE\/NEJMOA2103425_DATA-SHARING.PDF","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O et al (2021) Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 385(22):2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMOA2103425\/SUPPL_FILE\/NEJMOA2103425_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"4","key":"4456_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/0284186X.2017.1301680","volume":"56","author":"S Soni","year":"2017","unstructured":"Soni S, Padwad YS (2017) HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol 56(4):503\u2013515. https:\/\/doi.org\/10.1080\/0284186X.2017.1301680","journal-title":"Acta Oncol"},{"key":"4456_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejmech.2012.01.033","volume":"49","author":"Y Xia","year":"2012","unstructured":"Xia Y, Choi H-K, Lee K (2012) Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49:24\u201340. https:\/\/doi.org\/10.1016\/j.ejmech.2012.01.033","journal-title":"Eur J Med Chem"},{"issue":"9","key":"4456_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney KD, Infante JR, Lam ET et al (2018) Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol 36(9):867\u2013874. https:\/\/doi.org\/10.1200\/JCO.2017.74.2627","journal-title":"J Clin Oncol"},{"issue":"6","key":"4456_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2009.03.018","volume":"15","author":"Z Li","year":"2009","unstructured":"Li Z, Bao S, Wu Q et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501\u2013513","journal-title":"Cancer Cell"},{"issue":"18","key":"4456_CR35","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.4155\/fmc-2018-0163","volume":"10","author":"JJ Renfrow","year":"2018","unstructured":"Renfrow JJ, Soike MH, Debinski W et al (2018) Hypoxia-inducible factor 2\u03b1: a novel target in gliomas. Future Med Chem 10(18):2227\u20132236. https:\/\/doi.org\/10.4155\/fmc-2018-0163","journal-title":"Future Med Chem"},{"key":"4456_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-020-72290-2","author":"JJ Renfrow","year":"2020","unstructured":"Renfrow JJ, Soike MH, West JL et al (2020) Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-020-72290-2","journal-title":"Sci Rep"},{"issue":"21","key":"4456_CR37","doi-asserted-by":"publisher","first-page":"9691","DOI":"10.1021\/acs.jmedchem.8b01196","volume":"61","author":"PM Wehn","year":"2018","unstructured":"Wehn PM, Rizzi JP, Dixon DD et al (2018) Design and activity of specific Hypoxia-Inducible Factor-2\u03b1 (HIF-2\u03b1) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem 61(21):9691\u20139721. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01196","journal-title":"J Med Chem"},{"key":"4456_CR38","doi-asserted-by":"crossref","unstructured":"Courtney K, Infante J, Lam E, et al (2016) A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. In: ASCO Meeting Abstracts","DOI":"10.1200\/JCO.2016.34.15_suppl.2506"},{"key":"4456_CR39","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","volume":"76","author":"EM Wallace","year":"2016","unstructured":"Wallace EM, Rizzi JP, Han G et al (2016) A small-molecule antagonist of HIF2a is efficacious in preclinical models of renal cell carcinoma. Ther Targets Chem Biol. 76:5491\u20135500. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0473","journal-title":"Ther Targets Chem Biol."},{"issue":"7","key":"4456_CR40","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/J.CELREP.2017.07.049","volume":"20","author":"E Johansson","year":"2017","unstructured":"Johansson E, Grassi ES, Pantazopoulou V et al (2017) CD44 interacts with HIF-2\u03b1 to modulate the hypoxic phenotype of perinecrotic and perivascular glioma cells. Cell Rep 20(7):1641\u20131653. https:\/\/doi.org\/10.1016\/J.CELREP.2017.07.049","journal-title":"Cell Rep"},{"issue":"2","key":"4456_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.20517\/CDR.2019.96","volume":"3","author":"LM Nusblat","year":"2020","unstructured":"Nusblat LM, Tanna S, Roth CM (2020) Gene silencing of HIF-2\u03b1 disrupts glioblastoma stem cell phenotype. Cancer Drug Resist 3(2):199. https:\/\/doi.org\/10.20517\/CDR.2019.96","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"4456_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14(2):307\u2013320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6","journal-title":"Neurotherapeutics"},{"issue":"9","key":"4456_CR43","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/NEUONC\/NOV095","volume":"17","author":"BM Ellingson","year":"2015","unstructured":"Ellingson BM, Bendszus M, Boxerman J et al (2015) Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-oncology 17(9):1188\u20131198. https:\/\/doi.org\/10.1093\/NEUONC\/NOV095","journal-title":"Neuro-oncology"},{"issue":"11","key":"4456_CR44","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/NEUONC\/NOV106","volume":"17","author":"RJ Harris","year":"2015","unstructured":"Harris RJ, Cloughesy TF, Liau LM et al (2015) pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-oncology 17(11):1514\u20131524. https:\/\/doi.org\/10.1093\/NEUONC\/NOV106","journal-title":"Neuro-oncology"},{"issue":"5","key":"4456_CR45","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/MRM.27204","volume":"80","author":"RJ Harris","year":"2018","unstructured":"Harris RJ, Yao J, Chakhoyan A et al (2018) Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med 80(5):1962\u20131978. https:\/\/doi.org\/10.1002\/MRM.27204","journal-title":"Magn Reson Med"},{"issue":"3","key":"4456_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.18383\/J.TOM.2018.00017","volume":"4","author":"J Yao","year":"2018","unstructured":"Yao J, Ruan D, Raymond C et al (2018) Improving B 0 correction for pH-weighted amine proton Chemical Exchange Saturation Transfer (CEST) imaging by use of k-means clustering and lorentzian estimation. Tomography 4(3):123\u2013137. https:\/\/doi.org\/10.18383\/J.TOM.2018.00017","journal-title":"Tomography"},{"issue":"4","key":"4456_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/dmd.117.079723","volume":"46","author":"C Xie","year":"2018","unstructured":"Xie C, Gao X, Sun D et al (2018) Metabolic profiling of the novel hypoxia-inducible factor 2\u03b1 inhibitor PT2385 in vivo and in vitro. Drug Metab Dispos 46(4):336\u2013345. https:\/\/doi.org\/10.1124\/dmd.117.079723","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4456_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2133\/dmpk.dmpk-12-rv-085","volume":"28","author":"T Hirota","year":"2013","unstructured":"Hirota T, Eguchi S, Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28(1):28\u201337. https:\/\/doi.org\/10.2133\/dmpk.dmpk-12-rv-085","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"4456_CR49","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","volume":"26","author":"KD Courtney","year":"2020","unstructured":"Courtney KD, Ma Y, de Leon AD et al (2020) HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin Cancer Res 26(4):793\u2013803. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1459","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04456-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04456-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04456-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:11:36Z","timestamp":1699614696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04456-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["4456"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04456-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Roy E. Strowd serves as a consultant for Monteris Medical and Novocure. He receives an editorial stipend from the American Academy of Neurology. He has received research\/grant support from the American Academy of Neurology, American Society for Clinical Oncology, Southeastern Brain Tumor Foundation, Jazz Pharmaceuticals, and the International Association for Medical Science Educators. He receives royalties from Elsevier, Lecturio and Kaplan Medical. Dr. Benjamin Ellingson, Ms. Catalina Raymond, Dr. Jingwen Yao, Dr. Anna Piotrowski, Dr. Arati Desai, Dr. Frank Lieberman, Ms. Serena Desideri, Dr. Xiaobu Ye and Dr. Stuart Grossman has nothing to disclose. Dr. Patrick Wen has received research support from Astra Zeneca\/Medimmune, Beigene, Celgene, Chimerix, Eli Lily, Genentech\/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics, VBI Vaccines and serves on advisory boards for Astra Zeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, and VBI Vaccines. Dr. Manmeet Ahluwalia receives grants\/research support from Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, and Merck, consults for Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, AnHeart Therapeutics, Varian Medical Systems, and Cairn Therapeutics, is on the Scientific Advisory Board for Cairn Therapeutics and Pyramid Biosciences, and is a stock shareholder for Mimivax, Cytodyn, MedInnovate Advisors LLC. Dr. Jennifer Clarke has served as consultant for Servier Pharmaceuticals and Agios Pharmaceuticals. Research support from Servier Pharmaceuticals, Agios Pharmaceuticals, and Merck & Co. Dr. L. Burt Nabros, MD serves on scientific advisory board for Chimerix and chairs the data safety monitoring committee for CNS Pharma. M.P. has consulted for Bayer, is a member of the HI-TRON Scientific Management Board and holds patents for peptides for use in treating or diagnosing IDH1R132H positive cancers (EP2800580B1).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}